BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms

doi:10.1182/blood.2023022499

Holly Lee, Paola Neri, Nizar J Bahlis

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms

Cell Biology
Hematology
Immunology
Biochemistry

Bispecific antibodies that engage T cells to target B cell maturation antigen (BCMA) or G protein-coupled receptor class C group 5 member D (GPRC5D) have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory MM leading to the recent accelerated approval of teclistamab, elranatamab and talquetamab by health agencies. Future challenges however remain to define their optimal dosing schedule and duration, sequencing and integration with established anti-MM therapeutics as well as delineating the biological and clinical mediators of immune escape.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

Web-based, modern reference management
Collaborate and share with fellow researchers
Integration with Overleaf
Comprehensive BibTeX/BibLaTeX support
Save articles and websites directly from your browser
Search for new articles from a database of tens of millions of references

Try out CiteDrive

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

More from our Archive

Role of abscisic acid‐mediated stomatal closure in responses to pathogens in plants

<scp>SIRT1</scp> activation promotes bone repair by enhancing the coupling of type <scp>H</scp> vessel formation and osteogenesis

Plant Cryopreservation: Principles, Applications, and Challenges of Banking Plant Diversity At Ultralow Temperatures

Structure and Function of Auxin Transporters

Extracellular vimentin as a modulator of the immune response and an important player during infectious diseases

Next-Generation Therapies for Multiple Myeloma

Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?

Small-Molecule Approaches to Target Transcription Factors

Hematopoietic stem cell quiescence and DNA replication dynamics maintained by the resilient β-catenin/Hoxa9/Prmt1 axis

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy